

4th International Conference and Exhibition on

Biologics & Biosimilars

October 26-28, 2015 Baltimore, USA

AVX-470, an orally-delivered GI-targeted anti-TNF bio-better

Neil L Schauer
Avaxia Biologics, USA

Avaxia Biologics is a clinical-stage biopharmaceutical company developing gut-targeted bio-better therapeutics. TNF is a clinically validated target for gut inflammation, and blockbuster anti-TNF monoclonal antibodies are currently on the market to treat Ulcerative colitis and Crohn's disease. Discussion will center on the manufacturing of AVX-470, Avaxia's orally-delivered minimally absorbed anti-TNF biologic drug that acts locally in the GI tract. In contrast to first generation systemically delivered anti-TNFs, AVX-470 has low systemic exposure for greater safety, higher local concentration to drive efficacy and the convenience of oral administration. AVX-470 is manufactured cost effectively from bovine colostrum. Bovine antibodies derived from colostrum have been designed by nature to be naturally stable to the gut environment. AVX-470, a polyclonal product, simultaneously hits the same TNF epitopes associated with first generation blockbuster drugs. A newly developed gut-stable monoclonal antibody will be briefly mentioned.

Biography

Neil Schauer is a versatile executive level leader and scientist, with significant expertise in Biopharmaceutical Process Development and Manufacturing. He is currently Senior Vice President of Technical Operations at Avaxia Biologics and is Principal Consultant at Schauer Biologics Consulting. In recent years he served as Vice President of Process Sciences at Inspiration Biopharmaceuticals where he developed Bio-better blood coagulation factors and was Senior Director of Process Development, Global Biologics R&D at Hospira, where he was responsible for Bio-similar process development.

nschauer@avaxiabiologics.com

Notes: